Bethan Hopewell

Partner at Powell Gilbert LLP

Bethan Hopewell has worked on a number of the highest-profile cases to come before the UK Patents Court in recent years. Her practice focuses on advising clients on contentious IP matters, often with an international element, spanning a range of technologies and industry sectors. Her strong scientific background, which includes a DPhil in molecular biology, is particularly relevant to advising clients on complex multi-jurisdictional patent disputes, pharmaceutical regulatory issues and contested supplementary protection certificate (SPC) disputes in the life sciences sector and regulatory matters concerning pharmaceutical and healthcare technologies. While this is the core focus of her practice, she also advises on disputes in other technical fields, such as electronics and telecoms.

Dr Hopewell also provides freedom-to-operate and due diligence advice. In the contentious soft IP field, she advises clients on disputes concerning counterfeiting, brand and advertising issues.

Dr Hopewell represents clients in litigation before the UK Patents Court, the Court of Appeal and the Supreme Court. She also represents clients in opposition and appeal proceedings before the EPO. In the context of coordinating multi-jurisdictional patent matters, Dr Hopewell has considerable experience of actively assisting with litigation in various European courts.

Dr Hopewell’s cases include:

  • Warner-Lambert v Actavis (pregabalin);
  • Chugai v UCB (patent licence dispute);
  • Illumina v Ariosa (non-invasive pre-natal testing);
  • Chugai Pharmaceutical v UCB (patent licence dispute – antibody technology);
  • Unwired Planet v Huawei (telecoms);
  • Merck Sharp v Royalty Pharma Collection Trust (diabetes treatments – DPP-IV inhibitors);
  • Wobben Properties v Siemens (wind turbines);
  • Rovi v Virgin Media (electronics);
  • Eugen Seitz v KHS Corpoplast (polyethylene terephthalate plastic technology);
  • HTC v Gemalto (telecoms);
  • Eli Lilly v Human Genome Sciences (neutrokine alpha);
  • Eli Lilly v Human Genome Sciences (SPCs – neutrokine alpha);
  • Sandoz/ratiopharm v Napp (controlled-release oxycodone formulations);
  • Dr Reddy’s v Eli Lilly (olanzapine);
  • Monsanto v Cargill (GM crops); and
  • Ferag AG v Muller Martini Ltd (print trimming machinery)

Professional associations

  • CIPA

Firm details

Powell Gilbert LLP
85 Fleet Street
London EC4Y 1AE
United Kingdom

Contact details

See firm profile